Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3- carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis

Molecular Pharmaceutics

Volumn 4, Issue 6, 2007, Pages 919-928

  Doshi, Jignesh M ^a   Tian, Defeng ^a   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Bcl 2; Decomposition; HA 14 1; Reactive oxygen species

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DECOMPOSITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BENZOPYRANS; CULTURE MEDIA, SERUM-FREE; HUMANS; NITRILES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES;

EID: 37549018038     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp7000846     Document Type: Article

References (47)

1. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267, 1456-1462.
2. Reed, J. C. Bcl-2 family proteins. Oncogene 1998, 17, 3225-3236.
3. Adams, J. M.; Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 2001, 26, 61-66.
4. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discovery 2002, 1, 111-121.
5. Bouillet, P.; Cory, S.; Zhang, L. C.; Strasser, A.; Adams, J. M. Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev. Cell 2001, 1, 645-653.
6. Cory, S.; Huang, D. C.; Adams, J. M. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003, 22, 8590-8607.
7. Genta Proportion of patients who at the time of diagnosis overexpress Bcl-2 relative to a normal cellular population. http://www.genta.com/genta/ Products/bcl2.html. 2006.
8. Kim, R.; Emi, M.; Tanabe, K.; Toge, T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004, 101, 2491-2502.
9. Wang, J.; Liu, D.; Zhang, Z.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7124-7129.
10. Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J.; Wagner, G. A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors. J. Am. Chem. Soc. 2002, 124, 1234-1240.
11. Tzung, S.; Kim, K. M.; Basańez, G.; Giedt, C. D.; Simon, J.; Zimmerberg, J.; Zhang, K. Y. J.; Hockenbery, D. M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol. 2001, 3, 183-191.
12. Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; Cao, Y.; Guo, R.; Li, B.; Zhu, X.; Huang, Y.; Long, Y.; Roller, P. P.; Yang, D.; Wang, S. Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening. J. Med. Chem. 2001, 44, 4313-4324.
13. Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.: Zhai, D.; Kipps, T. J.; Reed, J. C.; Pellecchia, M. Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL. Chem. Biol. 2004, 11, 389-395.
14. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. Discovery, Characterization, and Structure-Activity Relationships Studies of Proapoptotic Polyphenols Targeting B-Cell Lymphocyte/Leukemia-2 Proteins. J. Med. Chem. 2003, 46, 4259-4264.
15. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. J.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. B.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
16. Petras, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis. J. Med. Chem. 2006, 49, 656-663.
17. Tang, G.; Yang, C. Y.; Nikolovska-Coleska, Z.; Guo, J.; Qiu, S.; Wang, R.; Gao, W.; Wang, G.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Wang, S. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J. Med. Chem. 2007, 50, 1723-1726.
18. Verhaegen, M.; Bauer, J. A.; Martin de la Vega, C.; Wang, G.; Wolter, K. G.; Brenner, J. C.; Nikolovska-Coleska, Z.; Bengtson, A.; Nair, R.; Elder, J. T.; Van Brocklin, M.; Carey, T. E.; Bradford, C. R.; Wang, S.; Soengas, M. S. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006, 66, 11348-11359.
19. Dai, Y.; Rahmani, M.; Corey, S. J.; Dent, P.; Grant, S. A Bcr/ Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2. J. Biol. Chem. 2004, 279, 34227-34239.
20. Lickliter, J. D.; Wood, N. J.; Johnson, L.; McHugh, G.; Tan, J.; Wood, F.; Cox, J.; Wickham, N. W. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 2003, 17, 2074-2080.
21. Su, Y.; Zhang, X.; Sinko, P. J. Exploration of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: A promising new approach to the treatment of multidrug resistant cancer. Cancer Lett. 2007, 253, 115-123.
22. Pei, X.; Dai, Y.; Grant, S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003, 17, 2036-2045.
23. Hao, J.; Yu, M.; Liu, F.; Newland, A. C.; Jia, L. Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells. Cancer Res. 2004, 64, 3607-3616.
24. Sinicrope, F. A.; Penington, R. C.; Tang, X. M. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells. Clin. Cancer Res. 2004, 10, 8284-8292.
25. Nimmanapalli, R.; O'Bryan, E.; Kuhn, D.; Yamaguchi, H.; Wang, H.; Bhalla, K. N. Regulation of 17-AAG-induced apoptosis: Role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003, 102, 269-275.
26. Pei, X.; Dai, Y.; Grant, S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol. Cancer Ther. 2004, 3, 1513-1524.
27. Skommer, J.; Wlodkowic, D.; Mättö, M.; Eray, M.; Pelkonen, J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk. Res. 2006, 20, 322-331.
28. Manero, F.; Gautier, F.; Gallenne, T.; Cauquil, N.; Grée, D.; Cartron, P.-F.; Geneste, O.; Grée, R.; Vallette, F. M.; Juin, P. The Small Organic Compound HA14-1 Prevents Bcl-2 Interaction with Bax to Sensitize Malignant Glioma Cells to Induction of Cell Death. Cancer Res. 2006, 66, 2757-2764.
29. Niizuma, H.; Nakamura, Y.; Ozaki, T.; Nakanishi, H.; Ohira, M.; Isogai, E.; Kageyama, H.; Imaizumi, M.; Nakagawara, A. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006, 25, 5046-5055.
30. An, J.; Chervin, A. S.; Nie, A.; Ducoff, H. S.; Huang, Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007, 26, 652-661.
31. Sutter, A. P.; Maaser, K.; Grabowski, P.; Bradacs, G.; Vormbrock, K.; Höpfner, M.; Krahn, A.; Heine, B.; Stein, H.; Somasundaram, R.; Schuppan, D.; Zeitz, M.; Scherübl, H. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J. Hepatol. 2004, 41, 799-807.
32. Milella, M.; Estrov, Z.; Kornblau, S. M.; Carter, B. Z.; Konopleva, M.; Tari, A.; Schober, W. D.; Harris, D.; Leysath, C. E.; Lopez-Berestein, G.; Huang, Z.; Andreeff, M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/ MAPK pathways in acute myelogenous leukemia. Blood 2002, 99, 3461-3464.
33. Oliver, L.; Mahe, B.; Gree, R.; Vallette, F. M.; Juin, P. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk. Res. 2007, 31, 859-863.
34. Lickliter, J. D.; Cox, J.; McCarron, J.; Martinex, N. R.; Schmidt, C. W.; Lin, H.; Nieda, M.; Nicol, A. J. Small-molecule Bcl-2 inhibitors sensitise tumor cells to immune-mediated destruction. Br. J. Cancer 2007, 96, 600-608.
35. Witters, L. M.; Witkoski, A.; Planas-Silva, M. D.; Berger, M.; Viallet, J.; Lipton, A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol. Rep. 2007, 17, 465-469.
36. Franke, C.; Noldner, M.; Abdel-Kader, R.; Johson-Anuna, L. N.; Gibson Wood, W.; Muller, W. E.; Eckert, G. P. Bcl-2 upregulation and neuroprotection in guninea pig brain following chronic simvastatin treatment. Neurobiol. Dis. 2007, 25, 438-445.
37. Wlodkowic, D. Skommer, J. Pelkonen, J. Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA 14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. Leuk. Res. 2007, XXX. (in press).
38. Kessel, D.; Reiners, J. J., Jr. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA 14-1. Cancer Lett. 2007, 249, 294-299.
39. Wlodkowic, D.; Skommer, J.; Pelkonen, J. Towards an understanding of apoptosis detection by SYTO dyes. Cytometry, Part A 2007, 71, 61-72.
40. Nsoure Obame, F. Zini, R. Souktani, R. Berdeaux, A. Morin, D. Peripheral Benzodiazepine Receptor-Induced Myocardial Protection is Mediated by Inhibition of Mitochondrial Membrane Permeabilization. J. Pharmacol. Exp. Ther. 2007, XXX. (in press).
41. Schwartz, P. S.; Manion, M. K.; Emerson, C. B.; Fry, J. S.; Schulz, C. M.; Sweet, I. R.; Hockenbery, D. M. 2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition. Mol. Cancer Ther. 2007, 6, 2073-2080.
42. An, J.; Chen, Y.; Huang, Z. Critical Upstream Signals of Cytochrome c Release Induced by a Novel Bcl-2 Inhibitor. J. Biol. Chem. 2004, 279, 19133-19140.
43. Doshi, J. M.; Tian, D.; Xing, C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3- carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J. Med. Chem. 2006, 49, 7731-7739.
44. Cathcart, R.; Schwiers, E.; Ames, B. N. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal. Biochem. 1983, 134, 111-116.
45. Bonsignore, L.; Cottiglia, F.; Maccioni, A. M.; Secci, D.; Lavagna, S. M. Synthesis of coumarin-3-O-acylisoureas by dicyclohexyl-carbodiimide. J. Heterocycl. Chem. 1995, 32, 573-577.
46. Munday, R. Autoxidation of naphthohydroquinones: Effects of metals, chelating agents, and superoxide dismutase. Free Radical Biol. Med. 1997, 22, 689-695.
47. Ollinger, K.; Buffinton, G. D.; Ernster, L.; Cadenas, E. Effect of superoxide dismutase on the autoxidation of substituted hydroand semi-naphthoquinones. Chem.-Biol. Interact. 1990, 73, 53-76.